Podcast Episode 2: The Ramifications of the FDA’s Unique Device Identification Rule with Dan Matlis of Axendia
Recently we had the opportunity to sit down with one of the world’s leading experts on the medical device industry, Daniel R. Matlis, president of Axendia. Axendia, a leading analyst and strategic advisory firm focused on the life science and healthcare markets, recently completed a survey of med-tech executives for its report on how the industry was responding to globalization. In this podcast, Matlis explains the FDA’s unique device identification rule issued this summer.
Read more →